PTPRC and neoplasm: Treatment with 08A09 decreased the percentage of suppressive granulocytic MDSCs (CD11b+Ly6G+Ly6CloMHCII−) among the tumor-infiltrating immune cells defined as viable CD45+ cells (Figure 7B).